Abstract: Described is the identification of ZnT8 as an autoantigen target in type I autoimmune diabetes (T1D), other autoimmune disease, and other diabetes-linked diseases and conditions. Also described are a variety of therapeutic, diagnostic, and prognostic tools and methods based on this discovery. The identification of genetic variation in ZnT8 as an important player in the initiation of the disease process and the progression of autoimmunity to clinical diabetes is disclosed.

Abstract: The detection of parietal cell autoimmune antibodies comprising an ATP4A D3.2 subdomain binding site can diagnose autoimmune body gastritis and/or pernicious anemia with extraordinary sensitivity and specificity that is far superior to existing commercial assays. Further, the assay has diagnostic applications for use in diagnosing type 1 diabetes, thyroiditis and Addison's disease. As pernicious anemia is typically a disease of the elderly, detection of parietal cell antibodies may precede clinical disease by many years if not decades, thereby allowing the initiation of therapeutic interventions such as vitamin B12 administration to prevent the development of pernicious anemia or immunologic interventions to prevent type 1 diabetes and its complications.

Abstract: A method and compositions for detecting autoimmunity to islet glucose-6-phosphatase related protein (IGRP). Detection of IGRP autoantibodies alone, and in combination with other molecules such as the 65-kDa form of glutamate decarboxylase (GAD65), insulin and insulin granule membrane proteins ICA512 (IA-2) and phogrin (IA2?) auto-antigens, provides an effective and reliable chemical assay for the diagnosis of autoimmune (type 1) diabetes. Additionally, this invention provides therapeutic regimens based on IGRP and related molecules for the amelioration of the diabetic clinical condition. Therefore, IGRP alone or in combination with other autoimmune diabetes associated antigens such as insulin, IA-2 and GAD65, is useful in the prediction (diagnosis), treatment (therapy), and prevention (prophylaxis) of diabetes.

Abstract: A method and compositions for detecting autoimmunity to islet glucose-6-phosphatase related protein (IGRP). Detection of IGRP autoantibodies alone, and in combination with other molecules such as the 65-kDa form of glutamate decarboxylase (GAD65), insulin and insulin granule membrane proteins ICA512 (IA-2) and phogrin (IA2?) auto-antigens, provides an effective and reliable chemical assay for the diagnosis of autoimmune (type 1) diabetes. Additionally, this invention provides therapeutic regimens based on IGRP and related molecules for the amelioration of the diabetic clinical condition. Therefore, IGRP alone or in combination with other autioimmune diabetes associated antigens such as insulin, IA-2 and GAD65, is useful in the prediction (diagnosis), treatment (therapy), and prevention (prophylaxis) of diabetes.

Abstract: A method and compositions for detecting autoimmunity to islet glucose-6-phosphatase related protein (IGRP). Detection of IGRP autoantibodies alone, and in combination with other molecules such as the 65-kDa form of glutamate decarboxylase (GAD65), insulin and insulin granule membrane proteins ICA512 (IA-2) and phogrin (IA2?) auto-antigens, provides an effective and reliable chemical assay for the diagnosis of autoimmune (type 1) diabetes. Additionally, this invention provides therapeutic regimens based on IGRP and related molecules for the amelioration of the diabetic clinical condition. Therefore, IGRP alone or in combination with other autioimmune diabetes associated antigens such as insulin, IA-2 and GAD65, is useful in the prediction (diagnosis), treatment (therapy), and prevention (prophylaxis) of diabetes.

Abstract: Described is the identification of ZnT8 as an autoantigen target in type I autoimmune diabetes (T1D), other autoimmune disease, and other diabetes-linked diseases and conditions. Also described are a variety of therapeutic, diagnostic, and prognostic tools and methods based on this discovery. The identification of genetic variation in ZnT8 as an important player in the initiation of the disease process and the progression of autoimmunity to clinical diabetes is disclosed.